Apellis Pharmaceuticals Inc. (APLS) and Cytori Therapeutics Inc. (NASDAQ:CYTX) Comparison side by side

Since Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and Cytori Therapeutics Inc. (NASDAQ:CYTX) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apellis Pharmaceuticals Inc. N/A 0.00 156.34M -2.05 0.00
Cytori Therapeutics Inc. 6.45M 0.86 13.86M -3.90 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Apellis Pharmaceuticals Inc. and Cytori Therapeutics Inc.


Table 2 has Apellis Pharmaceuticals Inc. and Cytori Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals Inc. 0.00% -48.3% -39.9%
Cytori Therapeutics Inc. -214.88% -261.3% -79.5%


14.9 and 14.9 are the respective Current Ratio and a Quick Ratio of Apellis Pharmaceuticals Inc. Its rival Cytori Therapeutics Inc.’s Current and Quick Ratios are 0.6 and 0.4 respectively. Apellis Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Cytori Therapeutics Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Apellis Pharmaceuticals Inc. and Cytori Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Apellis Pharmaceuticals Inc. 0 0 1 3.00
Cytori Therapeutics Inc. 0 0 0 0.00

The average target price of Apellis Pharmaceuticals Inc. is $45, with potential upside of 123.99%.

Insider and Institutional Ownership

Institutional investors held 59.3% of Apellis Pharmaceuticals Inc. shares and 6.8% of Cytori Therapeutics Inc. shares. Insiders held roughly 20.7% of Apellis Pharmaceuticals Inc.’s shares. On the other hand, insiders held about 2.42% of Cytori Therapeutics Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Apellis Pharmaceuticals Inc. 23.33% 31.79% 16.7% -2.95% -0.43% 39.88%
Cytori Therapeutics Inc. -8.29% -28.42% -26.18% -57.89% -92.62% -17.24%

For the past year Apellis Pharmaceuticals Inc. has 39.88% stronger performance while Cytori Therapeutics Inc. has -17.24% weaker performance.


Apellis Pharmaceuticals Inc. beats on 7 of the 10 factors Cytori Therapeutics Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The company also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and KaposiÂ’s Sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer. It serves hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through direct sales force, third-party distributors, independent sales representatives, and partners worldwide. The company was founded in 1996 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.